Prevalence of Urinary Tract Infection in Patients with Acute ST Segment Elevation Myocardial Infarction by Gokul, B J
PREVALENCE OF URINARY TRACT 
INFECTION IN PATIENTS WITH ACUTE 
ST SEGMENT ELEVATION 
MYOCARDIAL INFARCTION 
 
 
DISSERTATION SUBMITTED FOR  
M.D. DEGREE (BRANCH I) (GENERAL MEDICINE)  
SEPTEMBER 2006 
 
 
 
 
 
 
 
 
MADURAI MEDICAL COLLEGE, MADURAI 
THE TAMILNADU Dr. M.G.R. MEDICAL UNIVERSITY 
CHENNAI 
 
CERTIFICATE 
 
 
 
This is to certify that this dissertation entitled “PREVALENCE 
OF URINARY TRACT INFECTION IN PATIENTS WITH ACUTE 
ST SEGMENT ELEVATION MYOCARDIAL INFARCTION” 
submitted by Dr. B. J. GOKUL  to the Faculty of General Medicine, The 
Tamilnadu Dr. M.G.R. Medical University, Chennai in partial 
fulfillment of the requirement for the award of M.D. Degree Branch I 
(General Medicine) is a bonafide research work carried out by him 
under our direct supervision and guidance. 
 
 
 
Dr. A. Ayyappan M.D.,    Dr. P. Thirumalaikolundu  
Professor of Medicine,    Subramanian M.D., 
Chief III Medical Unit,    Professor and Head  
Department of Medicine    Department of Medicine 
Madurai Medical College   Madurai Medical College 
Madurai      Madurai 
 
 
DECLARATION 
 
 
 I, Dr. B.J. GOKUL, solemnly declare that the dissertation titled 
“PREVALENCE OF URINARY TRACT INFECTION IN 
PATIENTS WITH ACUTE ST SEGMENT ELEVATION 
MYOCARDIAL INFARCTION” has been prepared by me. 
 
 This is submitted to the Tamilnadu Dr. M.G.R. Medical 
University, Chennai in partial fulfillment of the rules and regulations for 
the M.D. degree Branch I (General Medicine). 
 
 
 
 
 
Place : Madurai 
Date :       Dr. B.J. Gokul 
 
 
 
 
 
ACKNOWLEDGEMENT 
 
 
 My sincere thanks to the Dean for permitting me to use the 
facilities of Madurai Medical College and Govt. Rajaji Hospital to 
conduct this study. 
 
 My Professor and Head of the Department of Medicine, Prof.         
Dr. P. Thirumalaikolundu Subramanian M.D, has always guided me, 
by example and valuable words of advice through the conduct of the 
study and also during my post graduate course. My sincere thanks to 
him. 
 
 I will ever remain in gratitude to my beloved chief                         
Dr. A. Ayyappan M.D. for guiding me through this study. 
 
 Knowledge and kindness abounds my beloved teachers,                 
Dr. Nalini Ganesh M.D, Dr. A.P. Selvaraj M.D., Dr. M. Kamaraj MD. 
Dr. A. Radhakrishnan M.D., Dr. Ashok kumar M.D, I owe them a lot 
and my sincere thanks to them. 
 
 My sincere thanks to Dr. A. Uma M.D, Additional Professor of 
Microbiology, Madurai Medical College for her valuable guidance. 
 
 I am thankful to Dr. R.V. Amuthan M.D., D.M., Assistant 
Professor of Cardiology, Department of Cardiology, Govt. Rajaji 
Hospital for his valuable support and guidance. 
 
 My heartfelt thanks to my Assistant Professors, Dr. L. Jerald 
Magellah MD., Dr. J. Sangumani M.D, and Dr. P.R. Sheela M.D, for 
their valuable suggestions. 
 
 Last but not the least, I sincerely thank all the patients who 
participated in the study, for their cooperation. 
 
 
 
 
 
 
 
 
 
CONTENTS 
 
 
S.No. Chapter Page No. 
1. Introduction 1 
2. Review of Literature 4 
3. Aim of the Study 34 
4. Materials and Methods 35 
5. Observations and results 41 
6. Discussion 48 
7. Summary 52 
8. Conclusion 54 
Bibliography 
Appendix I : Master chart 
Appendix II : Proforma 
 
GLOSSARY 
 
 
CAD / CHD   - Coronary Artery Disease / Coronary  
Heart Disease 
 
STEMI   - ST segment Elevation Myocardial  
Infarction 
 
HT    - Hypertension 
 
DM    - Diabetes Mellitus 
 
UTI    - Urinary Tract Infection 
 
LDL    - Low Density Lipo protein 
 
ED    - Endothelial Dysfunction 
 
GM-CSF   - Granulocyte – Macrophage Colony  
Stimulating Factor 
 
IL    - Interleukin 
 
TNF    - Tumor Necrosis factor 
 
TGF    - Transforming Growth Factor 
 
MCP    - Monocyte Chemotactic Protein 
NO    - Nitric Oxide 
 
CRP    - C – Reactive Protein 
 
ACS    - Acute Coronary Syndrome (s) 
 
PDGF   - Platelet Derived Growth Factor 
 
FGF    - Fibroblast Growth Factor 
 
TXA2    - Thromboxane A2 
 
CK-MB   - Creatine Kinase – MB Isoenzyme 
 
tPA    - Tissue Plaminogen Activator 
 
PCl    - Percutaneous Coronary Intervention 
 
EF    - Ejection Fraction 
 
RWMA   - Regional Wall Motion Abnormality 
 
ECG    - Electrocardiogram 
 
UFH    - Unfractionated Heparin 
 
LMWH   - Low Molecular Weight Heparin 
 
INTRODUCTION 
 
         Ischemic heart disease is now the leading cause of death 
worldwide1. WHO estimates that by 2020 the global number of deaths 
from coronary artery disease (CAD) will have risen from 7.1 in 2002 to 
11.1 million2. 
                  
Based on data from the Framingham Heart Study the lifetime 
risk of developing symptomatic CAD after age 40 is 49% for males and 
32% for females3. 
                  
CAD is most commonly due to obstruction of the epicardial 
coronary arteries by atheromatous plaque4. 
                  
Regarding the coronary hemodynamics little additional oxygen 
can be extracted from the blood in the coronaries, so increase in 
oxygen consumption requires increase in coronary blood flow. By 
reducing the lumen of the coronary arteries (especially when a 
stenosis reduces the cross sectional area by 75%) atherosclerosis 
limits its appropriate increase in perfusion when the demand for flow is 
augmented, as occurs during exertion or excitement5. This results in 
effort-induced angina. 
        A superficial erosion of the endothelium or a frank plaque 
rupture or fissure usually produces the thrombus that causes episodes 
of  unstable angina pectoris or the occlusive and relatively persistent 
thrombus that causes acute myocardial infarction. 
                
The major risk factors for atherosclerosis are smoking, 
hypertension, diabetes mellitus, high plasma LDL and low plasma HDL 
in addition to non-modifiable risk factors like age, sex, family history 
and genes. 
                
There are still subsets of patients where CAD occurs in the 
absence of the aforementioned risk factors. 
               
There is increasing evidence to suggest that inflammation plays 
a major role in the pathogenesis of atherosclerosis and therefore CAD. 
               
Several hypothesis have been postulated to account for the 
association between inflammation and coronary events including 
endothelial dysfunction (ED), cytokine interaction with coagulation 
factors and activation of proteases that promote plaque 
destabilization6. 
              
Subclinical infarction with respiratory pathogens such as 
Chlamydia pneumoniae as a potential stimulus had been the focus of 
many recent investigations. On the other hand less attention has been 
given to other common infection such as urinary tract infection (UTI) in 
promoting the inflammatory process and triggering acute coronary 
events. 
              
The aim of the present study is to determine if subclinical UTI is 
associated with acute coronary syndrome (especially ST segment 
elevation myocardial infarction - STEMI), to gain insight into whether 
an acute infection may play a role in triggering plaque rupture in 
patients with underlying CAD.          
 
 
 
                                                                       
   
  
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
REVIEW OF LITERATURE                                      
                                               
Coronary artery disease (CAD) has been defined as 'impairment 
of heart function due to inadequate blood flow to the heart compared 
to its needs caused by obstructive changes in the coronary circulation 
to the heart ' (WHO -1982)7. 
           
Epidemiology 
          The WHO has drawn attention to the fact that the CAD is an 
modern epidemic that may manifest itself in many presentations  
a) Angina pectoris of effort 
b) Cardiac failure  
c) Myocardial infarction  
d) Sudden cardiac death  
e) Cardiac arrhythmias  
 
        Epidemics of CAD began at different times in different countries. 
In US, it began in early 1920's; in Britain in 1930's and now the 
developing countries are catching up8. For example in Singapore the 
age standardized death rate from CAD has more than doubled in the 
past 20 years (rising from 22 per 100,000 population in 1957 to 50 per 
100,000 population in 1979). Similar trends were also noted in 
Malaysia, Sri Lanka and Mauritius. Countries where the epidemic 
began earlier are now showing a decline. This has been attributed to 
changes in life style and related risk factors (diet, cigarette use and 
exercise habits) plus better control of hypertension. 
                
CAD is a world wide disease. Mortality rates vary widely in 
different parts of the world. The highest mortality is seen in North 
Europe especially Finland, Scotland and Sweden. On the other hand 
Southern Europe and those in Japan are extremely low. 
           
Epidemiological transition 
          At the beginning of 20th century cardiovascular diseases (CVD) 
accounted for <10% of all deaths worldwide. At the beginning of 21st 
century CVD accounts for nearly half of all deaths in developed world 
and 25% in the developing world9. By 2020 its predicted that CVD will 
claim 25 million lives annually and that CVD will surpass infectious 
disease as world number one cause of death and disability. 
 
            Before 1900, infectious disease and malnutrition was the most 
common cause of death. This had been gradually supplanted in some 
(mostly developed) countries by chronic disease such as CVD and 
cancer, thanks largely to improved nutrition and public health 
measures. 
                
This shift in the diseases that account for the lion's share of 
morbidity and mortality is known as epidemiological transition10,11. 
This is tightly interlinked with changes in personal and collective 
wealth (economic transition), social structure (social transition), and 
demographics (demographical transition). Because the 
epidemiological transition is linked to the evolution of social and 
economic forces, it takes place at different rates around the world. 
 
CAD in Indians12,13,14 
 CAD afflicts Indians at a relatively younger age with severe and 
diffuse form of lesions. Prevalence of CAD has progressively 
increased in India during the latter half of the last century, particularly 
among urban population. 
 
 The conventional risk factors do not fill all the blanks in 
information. Infections may be one yet unrecognised factor. 
 
 The risk of CAD in Indians is 3-4 times higher than white 
Americans, 6 times higher than Chinese and 20 times higher than 
Japanese. It affects Indians 5-10 years earlier than other communities. 
The post infarction course is also worse with 3 times higher rate of 
reinfarction and 2 times higher rate of mortality. 
 
 Prevalence of CAD is 2 times higher (10%) in urban than in rural 
India. South Indians have higher prevalence; 7% in rural and 14% in 
urban areas. The vulnerability of urban Indians to CAD is possibly 
related to difference in nutritional, environmental factors and life style 
changes. 
 
              A large body of data exists on the occurance of CAD in 
hospitalised patients. However there are only two studies in its 
prevalence in general population. On screening of persons over age 
30 by 12 lead ECG in Chandigarh (urban), prevalence was 65.4% and 
47.8% per 1000 males and females respectively.       
           
Pattern of CAD in India reported to be as follows: 
a) CAD appears a decade earlier compared with age incidence 
in developed countries. Peak period is between 51-60. 
b) Males are affected more than females. 
c) Hypertension and diabetes account for 40% of the cases. 
d) Heavy smoking is responsible etiologically in a good number 
of cases. 
Evolution of concepts concerning pathogenesis of 
atherosclerosis 
 
  Until very recently most physicians viewed arteries as inanimate 
tubes rather than living dynamic tissue. 100 years ago Virchow 
recognised participation of cells in atherosclerosis. He viewed it as a 
proliferative disease but Rokitansky believed that atheroma derived 
from healing and resorption of thrombi15. 
                
Then in early twentieth century experiments using dietary 
modulation identified cholesterol as the culprit. This was followed by 
characterisation of human lipoprotein particles as the cause for 
atherosclerosis. We now recognise that elements of all these 
pathogenic theories participate in atherogenesis.  
 
Atherosclerosis – an inflammatory disease6 
    Atherosclerosis is an inflammatory disease. It is much more than 
high LDL cholesterol, which is considered to be the principal risk factor 
causing atheroma. Despite life style changes to curtail high 
cholesterol, CVD are on the rise. In fact, atherosclerotic lesions 
represent a series of highly specific cellular and a molecular response 
that is best described as an inflammatory disease. 
       The earliest lesion, the fatty streak is a pure inflammatory lesion 
with monocyte derived macrophages and T-lymphocytes secondary to 
lipoprotein accumulation. 
 
 Factors initiating and promoting inflammation: 
          Numerous pathophysiologic observations suggest exposure to 
injury hypothesis as first step in atherosclerosis. This emphasizes 
endothelial dysfunction (ED) rather than denudation as the first step, 
the causes of which are increased and modified LDL; free radicals 
caused by smoking, hypertension and diabetes mellitus; genetic 
alterations; increased plasma Homocysteine levels; infectious 
microorganisms like Herpes virus or Chlamydia pneumoniae or 
combinations of these.  
 
         The ED that results from injury increases its adhesiveness to 
leucocytes and platelets as well as its permeability. In addition cause it 
to have procoagulant (instead of anticoagulant) properties and to form 
vasoactive molecules: cytokines and growth factors. If the 
inflammatory response does not effectively neutralize/remove the 
offending agents, it can go indefinitely causing migration and 
proliferating of smooth muscle cells(SM) to produce intermediate 
lesion. This gradually thickens the arterial wall, which compensates by 
dilation for sometime before altering the diameter of the lumen. 
 
At every stage of the disease, the responses mediated by 
monocyte-derived macrophages and specific T-lymphocytes sub 
types. They multiply and elaborate hydrolytic enzymes; cytokines; 
chemokines and growth factors, which induce further damages and 
leads to further necrosis. 
                 
Thus, cycles of accumulation of mononuclear cells, migration 
and proliferation of SM cells and fibrous tissue proliferation leads to 
further enlargement and restructuring so that it becomes covered by a 
fibrous cap that overlie a core of lipid and necrotic tissue called 
advanced, complicated lesion. At some point, the artery no longer 
compensate by dilation the lesion may intrude into the lumen causing 
stenosis.   
 
How lipids cause inflammation? 
          When LDL particles become trapped in an artery, they undergo 
oxidation; glycation; aggregation; association with proteoglycans and 
incorporation into immune complexes. Lipid peroxide are then 
internalised by macrophages to become foam cells. Modified LDL is 
chemotactic for other monocytes and it upregulates expression of 
genes for M-CSF and MCP, thus expanding the inflammatory 
response. The mediators of inflammation (IL-1,TNF-α and M-CSF) 
increases LDL binding to endothelium and SM and thus increases LDL 
gene transcription. Thus a vicious cycle ensures. Therefore 
antioxidants (vitamin E) can have an anti-inflammatory effect.  
 
Role of homocysteine 
         Homocysteine is toxic to endothelium; is prothrombotic and it 
increases collagen synthesis and decreases availability of NO. 
Therefore high plasma homocysteine concentrations are associated 
with atherosclerosis. Trials are underway to determine whether 
treatment with Folic acid will prevent the progression or possibly even 
induce regression of atherosclerotic lesions. 
 
Hypertension 
    Angiotension two levels are often elevated in patients with 
hypertension. Its a potent vasoconstrictor, stimulates SM growth and 
by increasing its lipo-oxygenase activity it causes oxidation of LDL. 
Hypertension also increases free radical formation; reduces NO 
synthesis and increases leucocyte adhesion. 
 
Infection       
 An accumulation of clinical evidence shows that markers of 
inflammation correlate with coronary risk.16 for example, variation of 
plasma levels of C-reactive protein (CRP), as measured by a high 
sensitivity assay, can prospectively predict risk of myocardial 
infarction. CRP levels also correlate with outcome of patients with 
ACS. In control to several other novel risk factors, CRP adds predictive 
information to that derived from established risk factors such as 
cholesterol. Elevated levels of acute phase reactant, (APR) CRP may 
merely reflect ongoing inflammation rather than a direct etiologic role 
for CRP in CAD. Elevation in APR such as fibrinogen or CRP could 
reflect overall atherosclerotic burden and / or extravascular 
inflammation that could potentiate atherosclerosis or its 
complications17. In all likelihood, both factors contribute to elevation of 
inflammatory markers in patients at risk for coronary events. Indeed, 
lipid lowering therapy may reduce coronary events in part by reducing 
the inflammatory aspects of the pathogenesis of atherosclerosis. 
 
 One source of inflammatory stimulus could arise from infections 
agents. Interest has resurged in the possibility that infections may 
cause or contribute to atherosclerosis. A spate of recent publications 
has furnished evidence that supports a role of Chlamydia pneumoniae, 
Cytomegalovirus, or other infections agents in atherosclerosis and 
restenosis following coronary intervention18,19,20,21. 
 
 Infection combined with other factors may be responsible for the 
genesis of the lesions of atherosclerosis in some patients. 
 
Molecular aspects of atherosclerosis6 
      The earliest change that precedes atherosclerotic lesions takes 
place in the endothelium. This includes  
1. Increased endothelial permeability to lipoproteins mediated 
by NO, prostacyclin, PDGF, angiotensin two and endothelin. 
2. Up regulation of endothelial cell adhesion molecules 
including L-selectins, integrins and platelet-endothelial cell 
adhesion molecule 1 and up regulation of endothelial 
adhesion molecules which includes E-selectin, P-selectin, 
intercellular adhesion molecule 1 and vascular cell adhesion 
molecule 1. 
3. Migration of leucocytes into the arterial wall is mediated by 
oxidized LDL, monocyte chemotactic protein 1, IL-8, PDGF, 
M-CSF and osteopontin. 
  
Fatty streaks initially consist of lipid-laden monocytes and 
macrophages (foam cells) together with T-lymphocytes. Later they are 
joined by SM cells. Steps involved are  
1. Smooth muscle migration -stimulated by PDGF, FGF and 
TGF-ß  
2. T cell activation by TNF α, IL-2 and GM-CSF. 
3. Foam cell formation by oxidised LDL, M-CSF, TNF α and IL-1. 
4. Platelet adherence and aggregation by integrins, P-selectin, 
fibrin,TXA2, tissue factor etc. 
 
As these lesions progress to intermediate and advanced lesions 
they form fibrous cap. This covers a mixture of WBC'S, lipids and 
debris. These lesions expand at their shoulders by means of continued 
leucocyte adhesion and entry by same factors mentioned above. The 
necrotic core represents the results of apoptosis and necrosis; 
increased proteolytic activity and lipid accumulation. The fibrous cap 
forms as a result of increased activity of PDGF, TGF ß, IL-1,TNF α  
and osteopontin and of decreased connective tissue degradation. 
 
  
 
 
 
 
 
 
 
ACUTE CORONARY SYNDROMES 
ACUTE CORONARY SYNDROMES 
 
 Acute coronary syndromes (ACS) comprises patients with acute 
myocardial infarction with ST segment elevation on their presenting 
ECG (STEMI) and those with unstable angina (UA) and non ST 
segment elevation MI (NSTEMI). 
 
Unstable angina and Non – ST elevation myocardial infarction 
 The diagnosis of UA is based largely on clinical presentation. UA 
is defined as angina pectoris or equivalent ischemic discomfort. With 
atleast one of three features  
1. It occurs at rest usually lasting > 10 minutes. 
2. It is severe and of new onset (i.e. within the prior 4-6 
weeks) 
3. It occurs with a crescendo pattern (i.e. distinctly more 
severe, prolonged or frequent than previously). 
 
The diagnosis of NSTEMI is established if a patient with clinical 
features of UA develops evidence of myocardial necrosis, as reflected 
in elevated cardiac biomarkers. 
 
Pathophysiology 
 Four pathophysiologic factors may contribute  
1. Plaque rupture / erosion with superimposed non occlusive 
thrombosis. 
2. Dynamic obstruction (coronary spasm). 
3. Progressive mechanical obstruction. 
4. Secondary UA related to increased oxygen demand and / 
or decreased supply to myocardium (eg. Anemia). 
 
Clinical features 
 Substernal chest pain that frequently radiates to neck, left 
shoulder and left arm is present. Anginal equivalents such as dyspnea 
and epigastric discomfort may also occur. Clinical examination may be 
unremarkable or may include diaphoresis, cool skin, tachycardia, S3 
and / or S4, basilar rates and sometimes hypotension. 
 
Investigations 
 In UA, ST-segment depression, transient ST-segment elevation, 
and / or T-wave inversion occur in 30-50% of patients depending on 
the severity. 
 
 Patients with UA with elevated cardiac biomarkers (CK-MB and 
Troponin) are at increased risk of death or recurrent MI. 
 The 2002 American College of Cardiology / American Heart 
Association Guidelines22 include a clinical history typical of ischemic 
discomfort, a history of established CAD by angiography, prior MI, 
CHF, new ECG changes, or elevated biomarkers (High likelihood). 
Factors associated with intermediate likelihood includes age > 70 yrs, 
male gender, diabetes, known peripheral arterial or cerebrovascular 
disease and old ECG abnormalities. 
 
 The goals are  
1. Recognize or exclude MI (using cardiac markers). 
2. Evaluate for rest ischemia (chest pain at rest, serial or 
continuous ECGs) and  
3. Evaluate for significant CAD (using provocative stress 
testing). 
 
Risk Stratification 
 This is accomplished by TIMI scoring system23 (Thrombolysis in 
Myocardial Ischemia Trial) which includes seven independent risk 
factors age > 65 yrs, three or more risk factor for CAD, documented 
CAD at catheterization, development of UA/ NSTEMI while on aspirin, 
more than two episodes of angina within the preceding 24 hours, ST 
deviation > 0.5 mm and on elevated cardiac marker. 
TIMI Scoring System  
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Treatment 
 Anti-ischemic treatment is with nitrates (sublingual / IV), 
intravenous followed by oral (beta blockade), with or without calcium 
channel blockers. Antithrombotic therapy with a combination of aspirin 
and clopidogrel along with UFH / LMWH is added. For high risk 
patients, small molecular inhibitors eptifibatide and tirofiban holds 
promise. Multiple clinical trials have shown the benefit of early invasive 
strategy in high risk patients (eg. those with multiple risk factors, ST – 
segment deviation, and / or positive biomarkers). 
 
STEMI24 
 It is one of the most common diagnoses in hospitalized patients 
in industrialized countries. The early mortality (30 day) rate is around 
30%, with more than half of these deaths occurring before the 
individual reaches the hospital. Survival is markedly reduced in elderly 
patients more than 75 years. 
 
Diagnosis 
 The 12 lead ECG is critical for management since it 
distinguishes patients with ST elevation from those without ST 
segment elevation. Cardiac biomarkers distinguishes UA from NSTEMI 
and assesses the magnitude of STEMI 
 
Clinical features 
 Presentation is similar to angina but is severe and lasts longer. 
Other presentations include sudden loss of consciousness, acute 
confusional state, profound weakness, arrhythmias, evidence of 
peripheral embolism or unexplained drop in blood pressure. 
 
 The WHO criterion for MI diagnosis requires two of the following. 
1. Chest discomfort or an anginal equivalent. 
2. ECG changes consistent with ischemia or infarction. 
3. Elevated cardiac specific enzymes. 
 
On examination patients may have tachycardia/ hypertension 
(one fourth of patients with acute anterior wall infarction); or 
bradycardia and hypotension (one half of inferior wall infarction). 
Abnormal systolic pulsation by dyskinetic bulging of infarcted 
myocardium, signs of ventricular dysfunction like S3 and S4, soft S1 
and paradoxical splitting of S2. midsystolic or late systolic murmur due 
to dysfunction of mitral valve apparatus and pericardial friction rub 
(transmural infarction ) are also seen. 
 
Investigation 
 ECG shows ST elevation in leads depending on the wall type 
affected. Acute transmural anterior wall ischemia is reflected by ST 
elevations or increased T wave positivity in one or more of the 
precordial leads (V1 to V6) and leads I, and AVL. Inferior wall ischemia 
produces changes in leads II, III and AVF. Posterior wall ischemia may 
be recognized indirectly by reciprocal ST depression in leads V1 to V3. 
Right ventricular ischemia produces changes in right sided chest 
leads. When ischemic ST elevations occur as the earliest sign of acute 
infarction, they are followed by T inversions and often by Q waves. (Q 
wave and non Q wave infarction). With infarction, repolarisation (ST-T) 
abnormalities also occur. 
 
 Biomarkers like CK-MB isoenzyme has advantage over total CK. 
It rises within 4 to 8 hours, returns to normal by 48 to 72 hours. 
Cardiac specific troponin T and troponin I are now preferred as they 
are more specific. Levels remain elevated for 7 to 10 days. 
 
 Non-specific reaction to myocardial injury includes polymorpho 
nuclear leucocytosis and elevated erythrocyte sedimentation rate. 
  
         Abnormalities of wall motion (RWMA) on 2 – dimensional echo 
though cannot distinguish old from acute ischemia is very helpful. 
Radionuclide imaging techniques are also available in evaluating 
patients with suspected STEMI.  
 
Management 
 Aspirin is essential (160 to 325 mg stat) followed by 75 to 162 
mg daily orally. Control of pain is achieved with nitroglycerin 
(Sublingual / intravenous). Morphine and intravenous beta blockers 
are also helpful in this regard. Oxygen is given in patients with 
hypoxemia. 
  
 
 When ST – segment elevation of atleast 2 mm in two contiguous 
precordial leads and 1 mm in two limb leads is present, the patient 
should be considered for ‘reperfusion’ therapy. If the hospital is not 
capable of primary PCI, the patient is treated with fibrinolytic therapy. 
Other drugs used in management  includes antithrombotics, ACE 
inhibitors to prevent ventricular remodelling, and inotropics if and when 
needed. 
 
         
  
 
 
 
 
 
 
 
 
URINARY TRACT INFECTIONS 
URINARY TRACT INFECTIONS 
 
 Acute infections of the urinary tract can be subdivided into two 
anatomic categories; lower tract infection which are superficial 
(urethritis and cystitis) and upper tract Infections, which are usually 
invasive (acute pyelonephritis; prostatitis; intra renal and perinephric 
abscess). 
 
 These infections may occur independently or occur together; 
may be asymptomatic or symptomatic. 
 
ACUTE UTI 
 
Epidemiology 
 UTI are sub divided into catheter associated (Nosocomial) and 
non-catheter associated (or community acquired) infections. These 
infections occur in 1-3% of school girls and then increases markedly 
with onset of sexual activity. In young women the annual incidence is 
0.5 to 0.7 infections per patient year25. Acute symptomatic UTI are 
unusual in female under 50 yrs, while its quite common in between 20 
– 50 years. Asymptomatic bacteremia is more common among elderly     
and with rates as high as 40 to 50%. 
Etiology 
 The most common agents are gram negative bacilli (GNB). 
Escherichia coli causes 80% of acute infections in patients without 
catheters, urologic abnormalities, or calculi. Other organisms being 
Proteus, Klebsiella and Enterobacter. These organisms plus Serratia 
and Pseudomonas; assume importance in recurrent infections and 
infections associated with urologic manipulation, calculi or obstruction. 
Proteus and Klebsiella predispose to stone formation. 
 
 Gram positive cocci play a lesser role. Staphylococcus 
saprophyticus – coagulase negative, novobiocin – resistant species 
account for 10-15% of acute symptomatic UTI in young females. 
Enterococci and Staph aureus infects patients with renal stones or 
previous instrumentation. 
 
 In women with acute urinary symptoms, pyuria, and urine that is 
sterile, sexually, transmitted urethritis – producing agents such as 
Chlamydia trachomatis, Neisseria gonorrhoeae, herpes simplex virus 
are etiologically important. 
 
 Some other causes are Ureaplasma urealyticum, Mycoplasma 
hominis; Adeno viruses and Candida. 
Pathogenesis 
 In vast majority of UTIs, bacteria gain access to the bladder via 
the urethra. Ascent of bacteria from the bladder may follow and is 
probably the pathway for most renal parenchymal infections. 
 
 In females prone to cystitis, GNB (that normally reside in the 
bowel) colonize the introitus, periurethral skin, and distal urethra, 
predisposing factors being altered vaginal flora by antibiotics, other 
genital infections or contraceptives. Periurethral bacteria gain entry 
into the bladder by urethral massage during intercourse. Bacteria thus 
placed in the bladder are normally cleared partly through flushing but 
also due to antibacterial properties of urine (high urea concentration 
and high osmolarity of bladder urine). Prostatic secretions possess 
antibacterial properties. There is a role for locally produced antibodies 
as well. 
 
Conditions affecting pathogenesis 
1. Female gender 
2. Pregnancy 
3. Obstruction 
4. Neurogenic bladder 
5. Vesico ureteral reflex (VUR) 
6. Bacterial virulence factors 
7. Genetic factors 
 
Localization of infection 
 
Cystitis 
 Dysuria, frequency, urgency; suprapubic pain, malodorous, 
cloudy (sometimes bloody) urine are then features. Fever, nausea and 
vomiting usually indicate concomitant renal infection. 
 
Pyelonephritis 
 Fever, shaking chills, nausea, vomiting and diarrhoea are the 
features with or without symptoms of cystitis. Clinically fever, 
tachycardia, muscle tenderness, renal angle tenderness are present. 
Leucocyte casts in the urine is diagnostic. 
 
Urethritis 
 Presents with dysuria, frequency and pyuria. In case of sexually 
transmitted pathogens the onset is gradual without pain or hematuria. 
In case of cystitis due to E-coli pain, hematuria and abrupt onset are 
common. 
 
Diagnostic testing 
 Is with routine urine analysis, which shows ‘pyuria’. 
UTI exists when pathogenic micro organism are detected in 
urine, urethra, bladder, kidney or prostrate. Growth of > 105 organisms 
per ml from properly collected midstream “clean – catch” urine sample 
indicates infection. In symptomatic patients, a smaller number of 
bacteria (102-104/ml) may signify infection. In casea of suprapubic 
aspirates and samples from in dwelling catheter, colony counts of 102-
104/ml indicates infection. 
 
Treatment principles26 
1. Except in acute uncomplicated cystitis in females always do 
urine culture before empirical treatment. 
2. Predisposing factors (obstruction, calculi) should be corrected. 
3. Relief of symptoms does not always indicate bacteriological 
cure. 
4. Each treatment course is classified as failure (symptoms / 
bacteriuria not eradicated during therapy) or a cure (symptoms / 
bacteriuria both are eliminated). 
5. In general, upper tract infection requires longer treatment. 
6. Community negative infection are usually antibiotic sensitive. 
7. Suspect resistant strains in patients with repeated infections, 
instrumentation or recent hospitalisation. 
 
Prevention          
     Primary prevention is based on elimination or modification of risk 
factors of CAD like smoking, hypertension, diabetes, 
hypercholesterolemia, obesity, promoting physical activity and 
reduction of emotional stress. Treating homocysteinemia with folic acid 
to prevent CAD progression is under way. 
 
 Levels of inflammatory markers (like hs CRP) correlates with 
ACS outcomes. One source of inflammatory stimulus could arise from 
infectious agents. (Especially C. pneumonia, CMV etc.) At present no 
sufficiency proved clinical trial supports the use of antibiotics to reduce 
CHD risk. 
 
 Secondary prevention consists of early diagnosis and adequate 
treatment of CHD. Long term treatment with an antiplatelet agent 
(aspirin) after STEMI is associated with 25% reduction in the risk of 
recurrent infarction, strokes or cardiovascular mortality27. In these 
patients STEMI  tend to be smaller and are more likely to be non Q 
wave in nature. An alternative antiplalet agent is clopidogrel. Trials are 
underway to access the effectiveness and safety of aspirin and 
clopidogrel combination. ACE inhibitors should be used indefinitely by 
patients with clinically evidence heart failure, moderate decrease in 
global EF, or a large RWMA to prevent late ventricular remodeling and 
recurrent ischemic events28. The chronic use of oral β blocker for 
atleast 2 years after STEMI is supported by trials that demonstrated 
reduction in total mortality, sudden death and reinfarction. Warfarin is 
used in patients with high risk of embolism. 
 
Hurdles 
 The obstacles to implementation of current evidence based 
prevention and treatment of atherosclerosis include economics, education, 
physician awareness and patient adherence to recommended regimens. 
 
Future goals 
 Future goals in the field of treatment of atherosclerosis should 
include application of current knowledge regarding risk factor 
management and when appropriate, drug therapy.  
 
 We should begin anew rather than discard the possibility of 
expanding our limited knowledge base with regard to proatherogenic 
mechanisms (including viral vectors), include trials that better select 
target patients (those at an earlier stage of atherosclerosis or those 
with better markers of latent / active infection) and intervene them with 
novel anti infective agents and vaccines. 
  
 
 
 
 
 
 
ANALYSIS OF PUBLISHED 
REPORT 
ANALYSIS OF PUBLISHED REPORT 
 
 
1)  URINARY TRACT INFECTION IN PATIENTS WITH ACUTE 
CORONARY SYNDROMES: A POTENTIAL SYSTEMIC 
INFLAMMATORY CONNECTION (AHJ, VOLUME 149, NUMBER 
6). 
Sims JB, de Lemos JA, Maewal P, Warner JJ, Peterson JE, 
McGuire DK Department of medicine, university of Texas, 
Southwestern Medical Center, Dallas, U.S.A.          
     
This single-centre, case-control, retrospective study 
evaluated the prevalence of urinary tract infection (UTI) among 
100 consecutive ACS patients, compared with a contemporary 
control group undergoing elective coronary artery bypass graft 
(CABG) surgery. Cases were excluded if ACS was not 
confirmed by chart review or if urinalysis was not obtained within 
6 hours of arrival. Patients excluded from the control group were 
those with myocardial infarction within 21 days before CABG or 
without a preCABG urinalysis. 
 
The case and control groups were well matched, with the 
only significant differences being less congestive heart failure 
and more prior MI in the CABG control group. UTI was present 
in 27 of the ACS cases and 11 of the controls. Among ACS case 
patients, those with UTI tended to be older and more often 
women, with more diabetes, hyperlipidemia, hypertension and 
renal insufficiency and more commonly had non STEMI. In 
unadjusted analysis, UTI was three times more common in the 
cases versus controls; results were similar after multivariate 
adjustment. 
 
2)  WEEKLY INTERVENTION WITH ZITHROMAX FOR 
ATHEROSCLEROSIS AND ITS RELATED DISORDERS 
(WIZARD) TRIAL 
O'Conner CM, Dunne MW, Pfeffer MA et al., JAMA 2003; 
290; 1459-1466. 
 
This randomized controlled trial was the first to suggest a 
potential benefit for longterm antibiotic regimens. WIZARD 
randomized more than 7000 patients with a history of myocardial 
infarction and seropositivity of Chlamydia pneumoniae to 
Azithromycin 600 mg or placebo for 12 weeks. After 14 months, 
there was no significant risk reduction for all-cause death, 
nonfatal MI, coronary revascularisation; or hospitalisation for 
angina (hazard ratio 0.93; P=0.23). A trend toward therapeutic 
benefit was seen in men, diabetic subjects and smokers, but not 
in those with high baseline antibody titres of Chlamydia 
pneumoniae 
 
3)  ANTIBIOTICS IN CORONARY ARTERY DISEASE   
A) AZITHROMYCIN IN CORONARY EVENTS STUDY (ACES) 
j. thomas grayston, University of washington, seattle 
 
This randomized, double-blind placebo controlled trial 
which was sponsored by the National Institute of Health, 
enrolled 4012 adults with stable coronary heart disease without 
regard to their serologic Chlamydia pneumoniae status. 
Participants received weekly Azithromycin or placebo for one 
year. The mean period of follow up was four years. The primary 
end point, a composite of death due to coronary heart disease, 
nonfatal myocardial infarction, hospitalisation for unstable 
angina or coronary revascularisation occurred in 22.4% of the 
patients who received placebo and 22.3% of those who received 
Azithromycin -a relative risk reduction of less than 1%, with 
narrow confidence intervals. 
 
B) PRAVASTATIN OR ATORVASTATIN EVALUATION AND 
INFECTION THERAPY- THROMBOLYSIS IN MYOCARDIAL 
INFARCTION (PROVE IT- TIMI ) TRIAL TWO. 
Christopher P Cannon, MD., Brigham and women's hospital, 
Boston, Massachusetts. 
 
A double-blind randomized, two by two factorial trial 
involved 4162 patients at multiple centers, addressed two 
complementary issues. 
 
Results of second randomisation compared the results of 
treatment with Gatifloxacin and placebo, given after initial dosing 
for 10 days each month during a follow up period of 18 to 32 
months (mean 24 months). The primary end point- a composite 
of death from any cause, myocardial infarction, unstable angina 
requiring hospitalisation, revascularisation performed atleast 30 
days after randomisation, or stroke – occurred in 25.1% of the 
patients who received placebo and  23.7% of those who 
received Gatifloxacin; this represented a 5% reduction in hazard 
ratio, an insignificant difference  with narrow confidence limits.       
 
 
 
  
 
 
 
 
 
 
 
 
AIM OF THE STUDY 
AIM OF THE STUDY 
 
 
¾ To determine the prevalence of subclinical urinary tract 
infections and their bacteriological profile in patients with acute 
ST segment elevation myocardial infarction. 
 
¾ To examine any relationship of subclinical urinary tract 
infection with atherosclerotic risk factors like hypertension, 
diabetes, smoking or hyperlipidemia. 
  
 
 
 
 
 
 
 
MATERIALS AND METHODS 
MATERIALS AND METHODS 
 
Materials 
 The study included fifty patients with acute ST segment 
elevation myocardial infarction admitted in Intensive coronary care unit 
(ICCU) and Intensive medical care unit (IMCU) of Govt. Rajaji Hospital, 
Madurai. 
 
 Twentyfive age and sex matched patients with stable coronary 
artery disease (CAD) and with other acute medical emergencies 
admitted to IMCU were chosen as controls. 
 
 The study is a analytical study done between November 2005 to 
February 2006 over a period of 4 months.  
 
It was carried out in collaboration with the Department of 
Cardiology and Department of Microbiology. 
 
Informed consent was obtained from each case and control 
subject. 
 
There was no conflict of interest and it was not financially 
supported. 
The data collected from the case sheet of each patient included 
age, sex. A careful history was taken from each patient regarding 
personal habits like smoking; presence of atherosclerotic risk factors 
like hypertension, diabetes, hyperlipidemia; previous history of CAD 
and for history suggestive of urinary tract infection and obstruction. 
 
Blood samples were drawn for doing blood counts, blood sugar, 
urea, creatinine and fasting lipid profile. 
 
Urine samples were collected within six hours of hospital 
admission taking usual precautions (vide infra). 
 
All patients (cases and controls) also underwent 12 – lead 
electrocardiogram (ECG), Echocardiogram (ECHO) and ultra 
sonogram (USG) of prostate (male patients). 
 
Inclusion Criteria 
 All patients with ST elevation myocardial infarction who are 
admitted to ICCU / IMCU were included in my study. 
 
WHO definition of myocardial infarction 
 It requires the presence of atleast two of the following criteria  
1. A history of prolonged chest discomfort 
2. ECG changes consistent with ischemia or necrosis 
3. Elevated cardiac enzymes 
 
Exclusion Criteria 
1. All patients with symptomatic UTI. 
2. Patients who gave history of previous urethral catheterization 
or instrumentation. 
3. Patients with history suggestive of urinary tract obstruction 
were excluded. 
4. Patients who gave history of recurrent UTI or had been 
treated for UTI in the recent past. 
5. Patients whose USG showed enlarged prostate and / or 
significant residual volume of urine. 
6. When urine sample was not obtained within 6 hours of 
admission. 
 
Controls 
 Age and sex matched controls with stable CAD admitted to 
IMCU for medical emergencies other than acute coronary syndromes 
were selected for the study.  
 
Method32 - Collection and processing of urine 
 
Specimen collection in males 
 The male patients were instructed as follows. Retraction of 
prepuce and washing the area with soap and water; collect mid stream 
urine in a sterile screw capped container after voiding the first portion 
of urine. 
 
In females 
 The following instructions were given. 
1. To wash the external genitalia with soap and water. Not to 
use antiseptics. 
2. Collect midstream urine with labia majora held apart with 
fingers of left hand, with fingers of right hand holding the 
sterile wide mouthed container. 
 
The urine samples were transported to the Institute of 
Microbiology, Madurai Medical College, Madurai within half an hour. If 
delay was unavoidable it was refrigerated before transport (2 hours). 
 
Preparation of Smears 
 A loopful trial (4 mm diameter loop) of well mixed, uncentrifuged 
urine is placed on a clean glass slide. Without spreading, it was 
allowed to dry, heat fixed and stained with gram stain. It is then 
examined when microscope for pus cells, epithelial cells and bacteria. 
 
Inoculation into culture media 
 Calibrated loop method was used to count the bacteria, which is 
a simple, more rapid, less expensive and satisfactory method. 4 mm 
nichrome loop delivers 0.01 ml of urine. Nutrient agar plate, blood agar 
plate and MacConkey agar plate were inoculated using the above loop 
and the plates were incubated overnight at 370c. 
 
The number of colonies on each plate is counted. The number of 
viable bacteria present in 1 ml of undiluted urine is then calculated. 
 
< 1000 colonies / mL           insignificant bacteriuria, UTI  
unlikely for midstream urine. 
Significant for cystoscopic and 
suprapubic samples. 
 
10,000 – 1,00,000 colonies / mL Probably significant bacteriuria.  
Repeat specimen indicated. 
 
> 1,00,000 colonies / mL   Significant bacteriuria. UTI  
certain. 
The bacteria were identified by colony morphology and 
biochemical tests. Antimicrobial susceptibility by disc diffusion 
technique was carried out with antibiotic impregnated discs. 
 
Statistical methods 
 Descriptive statistics (mean values for continuous variables and 
percentages of discrete variables) were generated for baseline 
demographic and clinical characteristics and were compared using 
student 't' test for continuous and Chi-square tests for categorical 
variables. Relative risk was determined. P value < 0.05 was 
considered significant. 
 
  
 
  
 
 
 
 
 
 
 
OBSERVATIONS AND RESULTS 
OBSERVATIONS AND RESULTS 
 
 Fifty patients with acute ST segment elevation myocardial 
infarction admitted to IMCU / ICCU were chosen for the study (cases). 
Twentyfive patients with stable CAD with other acute medical 
emergencies admitted to IMCU were chosen as controls. 
 
CLINICAL CHARACTERISTICS OF PATIENTS AT BASELINE 
BY CASE VERSUS CONTROLS 
 
Age and Sex distribution of case and controls 
Table 1 
 
Cases and 
Controls 
Male Female Among both 
males and females 
Mean 50.14 66.83 52.14 
Case 
SD 10.53 7.41 11.53 
Mean 54.27 55.67 54.44 
Control 
SD 8.5 9.5 8.43 
P value > 0.05 > 0.05 > 0.05 
 
 This shows that the baseline demographics were similar 
between case and controls (‘p’ > 0.05) 
 
Baseline characteristics – hypertension 
Table 2 
 
Variable 
hypertension 
Cases Controls Total P value 
Present 17 9 26 
Not present 33 16 49 
Total 50 25 75 
0.8638 
 
 P value is > 0.05 (0.86) and is therefore not significant. This 
shows that cases and controls were similar with regard to the presence 
of hypertension and therefore well matched. 
 
Baseline characteristic – diabetes 
Table 3 
 
Variable 
Diabetes 
Cases Controls Total P value 
Present 19 8 27 
Not present 31 17 48 
Total 50 25 75 
0.6098 
 
 ‘P’ value is > 0.05 (0.60) and is not significant. Cases and 
controls were similar with regard to the presence of diabetes. 
Baseline characteristic – Hyperlipidemia 
Table 4 
Variable 
Hyperlipidemia 
Cases Controls Total P value 
Present 35 17 52 
Not present 15 8 23 
Total 50 25 75 
0.8595 
 
 ‘P’ value is 0.8595 (>0.05). Presence of hyperlipidemia is similar 
between cases and controls. 
 
Baseline characteristic – Smoking 
Table 5 
Variable 
Smoking 
Cases Controls Total P value 
Present 31 15 46 
Not present 19 10 29 
Total 50 25 75 
0.8668 
 
 ‘P’ value is 0.86 (> 0.05). Presence of Smoking is similar 
between cases and controls. 
 
Presence of UTI in case versus controls 
Table 6 
 
Urine culture Cases Controls Total P value 
Positive 11 3 14 
Negative 39 22 61 
Total 50 25 75 
0.2948 
 
 11 out of 50 (22%) of cases had UTI, whereas 3 out of 25 (12%) 
of controls had UTI. P value was 0.2948 (P > 0.05) and is not 
significant. But RR (Relative risk) was 1.23 (RR>1) indicating positive 
association between STEMI and UTI. 
 
CLINICAL CHARACTERISTICS OF CASES (STEMI)  
BY PRESENCE OF UTI 
 
Hypertension and UTI 
Table 7 
 
Variable UTI 
(N=11) 
No UTI 
(N=39) 
t P value 
Hypertension 7 10 
Percentage 63.63 25.6 
2.3597 0.0224 
 
 Among patients (cases) with UTI 63.63% were hypertensives 
and in those without UTI only 25.6 % were hypertensives. ‘p’ is 
significant (p < 0.05). 
 
Diabetes mellitus and UTI 
Table 8 
 
Variable UTI 
(N=11) 
No UTI 
(N=39) 
t P value 
Diabetes 3 16 
Percentage 27.27 41.02 
0.8834 0.3814 
 
 Among patients with UTI 27.27% were diabetics and in those 
without UTI only 41.02 % were diabetics. But this difference is not 
statistically significant (p = 0.38). 
 
Hyperlipidemia and UTI 
Table 9 
 
Variable UTI 
(N=11) 
No UTI 
(N=39) 
t P value 
Hyperlipidemia 7 28 
Percentage 63.63 71.79 
0.5037 0.6167 
 
 63.63% of patients with UTI and 71.79% of patients without UTI 
had hyperlipidemia and this difference is not significant statistically (p = 
0.61). 
 Smoking and UTI 
Table 10 
 
Variable UTI 
(N=11) 
No UTI 
(N=39) 
t P value 
Smoking 6 25 
Percentage 54.54 64.10 
0.5667 0.5735 
 
 In patients with UTI, 54.54% were smokers whereas 64.10% of 
patients without UTI were smokers but the difference is not statistically 
significant (p = 0.57). 
 
  
 
 
 
 
 
 
 
DISCUSSION 
DISCUSSION 
 
Fifty patients with acute ST segment elevation myocardial 
infarction admitted to IMCU / ICCU of Government Rajaji Hospital, 
Madurai during the period of Nov 2005 to Feb 2006 were included in 
the study. 
 
Twentyfive patients admitted to IMCU with acute medical 
emergencies other than ACS were chosen as controls. 
 
Mean age was 50.14 among male cases (SD 10.53) and 54.27 
among male controls (SD 8.5) and P value was > 0.05. Mean age was 
66.83 among female cases (SD 7.41) and 55.67 among female 
controls (SD 9.5) and p value was > 0.05. Therefore the case group 
and control group were well matched with respect to age and sex. 
 
17 out of 50 cases (34%) and 9 out of 25 controls (36%) had 
hypertension. P value was 0.86 (>0.05). 
 
19 out of 50 cases (38%) and 8 out of 25 controls (32%) had 
diabetes at baseline. P value was 0.60 (>0.05). 
 
Similarly 35 out of 50 cases (70%) and 17 out of 25 controls 
(68%) had hyperlipidemia. P value was 0.85 (> 0.05). 
 
Regarding smoking, 62% (31 out of 50) of cases and 60% (15 
out of 25) controls were smokers. P value was 0.86 (>0.05). 
 
Therefore case and control groups were well matched with 
respect to hypertension, diabetes, hyperlipidemia and smoking. 
Therefore the cases and controls are very much comparable. 
 
11 out of 50 (22%) of cases had subclinical UTI, whereas 3 out 
of 25 (12%) of controls had UTI.  P value was 0.2940 (P > 0.05) and is 
not significant. However the relative risk (RR) was 1.23 (RR>1) 
indicating the positive association between STEMI and UTI. This 
observation was similar to earlier study by John B. Sims et al which 
stated that subclinical UTI was 3 times more common in the cases 
than among controls. This discrepancy is probably because of the fact 
that in my study UTI was diagnosed based on urine culture rather than 
on counting number of white blood cells per high power field on urine 
analysis. 
 
The following organisms were isolated. Four patients had 
E.coli.Two patients had K.pneumoniae. Two patients had S.aureus. 
Two patients had Pseudomonas. One patient had Coagulase-negative 
Staphylococcus.  
Among cases with UTI 63.63% were hypertensives compared to 
25.6 % in those without UTI (p=0.02). Therefore among STEMI 
patients, those with UTI more often had hypertension than those who 
did not. This observation was similar to earlier study by John B. Sims 
et al.  
Other risk factors like diabetes, smoking and hyperlipidemia 
were more commonly observed in patients with UTI. However they 
were not statistically significant. 
 
Given the association between subclinical measures of systemic 
inflammation and CAD development, progression, and instability29, it is 
plausible that inducers of systemic inflammation such as subclinical 
infections (bacterial or viral) may play a direct role in triggering STEMI. 
A potential link between acute infection and complications of 
atherosclerosis was first described as early as 1897 by Sir William 
Osler. A number of studies have implicated infections agents such as 
Herpesvirus; Cytomegalovirus, C. pneumoniae, Helicobacter pylori and 
other infections pathogens in the atherosclerotic disease process. 
Moreover, acute bacterial respiratory tract infections have been linked 
to acute MI30. 
 
Chronic and acute infections may trigger plaque rupture via 
nonspecific inflammatory mechanisms. For example, the presence of 
elevated WBC count, independent of etiology; was a risk factor for MI 
in a cohort study.31 These observations suggest that systemic 
inflammation may precipitate ACS events. 
 
UTI is associated with a systemic host response, whether 
bacteremia occurs. The bacterial attachment to uroepithelial cells 
activate a cytokine cascade that includes the release of IL-1, IL-6 and 
IL-8 followed by neutrophil and other inflammatory cell recruitment. 
Local cytokine activation may thus induce systemic inflammation, 
promote plaque instability and thrombosis formation. This mechanism 
may in part explain the observation in the present study that UTI is 
associated with incident STEMI. 
 
The limitation of this study is that urine was not cultured for 
organisms other than bacteria. For example fungal culture and culture 
for chlamydia, or mycoplasma was not done as they are not routinely 
available. These investigations could have detected more number of 
UTI cases and therefore could have contributed to greater association 
with STEMI. 
 
SUMMARY 
 
 The study ‘’Prevalence of urinary tract infection in patients with 
acute ST segment elevation myocardial infarction” was conducted 
among 50 patients admitted in ICCU / IMCU and 25 controls admitted 
in IMCU of Government Rajaji Hospital, Madurai. 
 
 From the patients who satisfied inclusion criteria, urine samples 
were collected for culture within 6 hours of admission. All patients were 
subjected to detailed history taking, clinical examination, blood 
investigations in addition to 12 lend ECG, Echo and USG of prostate. 
 
 The baseline demographic and clinical characteristics were 
similar between cases and controls.  
 
 Among cases with STEMI, 11 out of 50 (22%) had UTI whereas 
3 out of 25 (12%) of controls had UTI. The relative risk (1.23) was > 1 
indicating positive association between STEMI and UTI. Predominantly 
Gram Negative Bacilli(GNB) were isolated. 
 
 
 
Regarding risk factors, 63.63% of cases with UTI were 
hypertensives compared to 25.6 % of cases without UTI. Therefore 
UTI patients more often had hypertension than their counterparts 
without UTI. 
 
 Other risk factors like diabetes, smoking and hyperlipidemia 
though more commonly observed in patients without UTI, could not be 
correlated as it was not statistically significant. 
 
CONCLUSION 
 
1. The prevalence of subclinical UTI in STEMI  patients is found 
to be higher when compared to controls.  
 
2. UTI is positively associated with ST segment elevation 
myocardial infarction. 
 
3. Among patients with STEMI, those with UTI more often had 
hypertension. 
 
4. Patients with combined UTI and hypertension had higher risk 
of developing STEMI. 
 
5. Gram Negative Bacilli especially Escherichia Coli was the 
commonest organism isolated in STEMI patients with 
subclinical UTI. 
 
6. Among STEMI patients, other risk factors like diabetes, 
smoking and hyperlipidemia are not significantly associated 
with UTI. 
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PROFORMA 
 
 
DEPARTMENT OF MEDICINE AND CARDIOLOGY 
PREVALENCE OF URINARY TRACT INFECTION IN ST SEGMENT 
ELEVATION MYOCARDIAL INFARCTION 
 
1. Name  :    2. Age / Sex : 
 
3. Ward / Unit :    4. OP/IP Number : 
 
5. Address : 
 
 
 
6. Presenting Illness : 
 Complaint : 
 Duration : 
 
7. Past History  : 
  HT  : Yes / No  Duration : 
  DM  : Yes / No  Duration : 
  MI  : Yes / No  Duration : 
 Hyperlipidemia : Yes / No  Duration : 
 
8. Personal History : 
  Smoking : Yes / No  Duration : 
  Alcoholism : Yes / No  Duration : 
 
9. Family History : 
 Premature CAD : Yes / No 
 
10. Symptoms of UTI / lower urinary tract obstruction :  
     No   Yes 
 
 
11. Physical Examination: 
  Obese : Weight  BMI 
    Height  
    Waist 
    HIP 
 
  Pulse : 
  BP : 
  CVS  : 
  RS  : 
 
11. Diagnosis  : 
 
12. Investigations : 
  Blood  : TC    ESR 
     DC 
     Hb% 
 
  Urine analysis: Alb 
     Sugar  
     Deposits 
 
  Urine Culture :  
 
 
 
         Total C : 
  Blood Sugar  :    TGL  : 
  Blood Urea  :    LDL  : 
  Serum Creatinine :    HDL  : 
         VLDL  : 
 
13. ECG : 
  Rate   : 
  Rhythm  : 
  Axis  P : 
    QRS : 
 
  Intervals PR : 
    QRS : 
    QT : 
    QTc : 
 
  Q wave  : 
 
  ST-T changes : 
 
  Others  : 
 
  Remarks  : 
 
14. ECHO    : 
 
15. USG Abdomen  : 
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 1 31 M 2 2 2 1 1 - 12200 + - 37 1.0 30 N No 
 2 60 M 1 1 1 1 1 - 8700 - - 19 0.7 56 N No 
 3 42 M 2 2 1 1 1 + 12000 + + 19 1.0 42 N No 
 4 47 M 2 2 1 1 2 + 9000 - - 29 0.9 70 N No 
 5 60 F 1 1 1 2 2 + 8000 - - 20 0.9 65 N No 
 6 55 M 1 1 1 2 1 + 11700 + + 42 1.4 37 N No 
 7 70 M 2 2 1 1 2 + 8000 - - 31 1.0 48 N No 
 8 37 M 2 2 1 1 1 + 9700 - - 35 0.9 35 N No 
 9 70 M 1 1 1 1 2 - 9500 - - 37 1.5 50 N No 
10  46 M 2 1 1 2 1 - 11900 - - 32 1.0 54 N No 
11 38 M 2 2 1 1 1 + 9000 - - 28 0.9 33 N No 
12 55 M 2 2 1 1 1 + 12600 + + 17 0.9 37 N No 
13 60 M 2 2 2 2 1 + 9000 - - 28 0.7 40 N No 
14 36 M 2 2 2 1 2 - 12400 - - 33 1.4 45 N No 
15 60 F 2 2 1 2 1 - 12100 - - 20 0.7 42 N No 
16 28 M 2 2 1 2 1 + 8000 - - 20 0.8 50 N No 
17 38 M 2 2 1 1 1 - 11800 - - 22 0.7 40 N No 
18 52 M 1 2 1 2 1 + 8200 - - 34 1.0 42 N No 
19 45 M 1 1 1 1 2 + 9000 - - 31 0.9 47 N No 
20 69 F 1 1 1 2 1 + 9300 - - 34 1.0 40 N No 
21 52 M 1 2 2 2 1 + 10200 - - 20 0.8 49 N No 
22 65 M 1 2 1 1 1 - 10700 + + 54 1.6 43 N No 
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23 52 M 1 1 1 2 2 - 11200 - - 87 2.5 66 N No 
24 71 M 1 1 2 2 1 + 10000 + + 24 0.9 45 N No 
25 50 M 1 1 1 1 1 + 8200 - - 31 1.0 44 N No 
26 46 M 2 2 1 1 1 + 9800 - - 19 0.8 40 N No 
27 47 M 2 2 2 1 1 - 10800 + - 21 0.8 42 N No 
28 50 M 2 1 2 1 2 - 9800 - - 26 0.9 40 N No 
29 42 M 2 2 1 2 1 + 9800 - - 38 1.0 40 N No 
30 67 F 1 2 1 2 1 + 11200 + + 19 0.8 39 N No 
31 55 M 2 2 1 2 2 - 9800 - - 24 1.1 47 N No 
32 55 M 2 1 2 1 2 - 9600 - - 53 1.4 36 N No 
33 55 M 2 2 1 1 2 + 8000 - - 27 1.2 47 N No 
34 56 M 1 2 2 1 2 + 8200 - - 32 1.3 46 N No 
35 69 M 2 2 2 1 2 - 10800 + + 49 1.8 72 N No 
36 80 F 1 1 1 2 2 + 12200 + + 23 0.9 44 N No 
37 62 M 2 2 2 2 1 + 8000 + + 44 1.1 39 N No 
38 50 M 2 1 2 2 1 + 8200 - - 45 1.4 28 N No 
39 60 M 1 2 1 1 1 + 10800 + + 39 0.8 42 N No 
40 47 M 1 1 2 1 1 + 9000 - - 26 0.9 44 N No 
41 46 M 2 2 1 1 1 + 8000 - - 14 0.6 41 N No 
42 52 M 2 1 1 1 1 + 11800 - - 28 0.9 56 N No 
43 53 M 2 2 1 1 1 - 10800 - - 32 1.0 40 N No 
44 50 M 1 2 2 1 1 + 11200 + + 29 0.9 39 N No 
45 40 M 2 2 2 1 2 + 8400 - - 21 0.8 47 N No 
46 43 M 2 1 1 2 1 - 8800 - - 25 1.3 44 N No 
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47 53 M 2 2 1 1 1 + 12800 - - 45 1.4 38 N No 
48 45 M 2 1 1 1 2 + 9600 - - 22 0.8 46 N No 
49 30 M 2 2 1 1 1 - 11200 - - 22 0.9 34 N No 
50 65 F 2 1 1 2 1 - 13700 - - 18 0.9 44 N No 
                 
1 55 M 2 2 1 1 1 + 9400 - - 32 0.8 Y N No 
2 60 M 2 1 1 2 2 - 8800 - - 27 0.9 Y N No 
3 65 F 2 2 2 2 2 + 8600 - - 236 11.5 Y N No 
4 47 M 1 1 1 1 1 + 7800 - - 18 1.2 Y N No 
5 40 M 2 2 1 1 1 - 9200 - - 21 1.1 Y N No 
6 54 M 1 2 2 1 2 + 8400 - - 15 0.9 Y N No 
7 57 M 1 1 1 2 1 - 9900 + + 22 1.0 Y N No 
8 45 M 2 2 2 1 1 + 7400 - - 18 0.7 Y N No 
9 46 M 2 1 1 1 1 + 6400 - - 25 1.2 Y N No 
10 64 M 1 1 1 2 2 - 5800 - - 28 0.9 Y N No 
11 55 M 2 2 2 1 2 + 8000 - - 30 0.7 Y N No 
12 50 M 1 2 1 2 1 + 7800 - - 23 1.2 Y N No 
13 70 M 1 1 1 2 2 - 10000 + + 27 0.8 Y N No 
14 65 M 2 2 1 1 1 + 7100 - - 29 0.8 Y N No 
15 46 F 2 2 2 2 1 + 9200 - - 31 1.1 Y N No 
16 58 M 2 2 1 1 1 + 8200 - - 19 0.7 Y N No 
17 49 M 2 2 1 1 2 + 7800 - - 17 1.0 Y N No 
18 44 M 2 2 1 2 1 + 9600 - - 20 0.8 Y N No 
19 67 M 1 1 1 1 2 - 10200 + + 30 1.0 Y N No 
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20 47 M 2 2 2 1 1 + 11400 - - 25 0.8 Y N No 
21 56 F 2 2 1 2 1 - 9600 - - 35 0.8 Y N No 
22 65 M 2 2 2 2 2 - 8700 - - 19 0.6 Y N No 
23 57 M 2 2 2 1 1 - 6600 - - 23 0.9 Y N No 
24 44 M 1 1 1 1 1 + 5800 - - 25 1.0 Y N No 
25 55 M 1 2 1 1 2 - 9800 - - 27 1.1 Y N No 
 
 
 Abbreviations in  Master Chart 
 
          Hypertension                                                 Thrombolysed 
                      1-   Present                                                 + - Yes 
2- Absent                                                  - -  No 
          Diabetes                                                         Pus cells 
1- Present                                                  > or =5/hpf  + 
2- Absent                                                          <5/hpf  -  
         Hyperlipidemia                                               USG 
1- Present                                                  N = Normal 
                      2-  Absent                                          Uti/Uto - No 
        Smoking                                                               Symptoms of Urinary tract  
1- Present                                        infection / Urinary tract obstruction 
2- Absent                                         is absent 
        Type of MI 
1- Antr. Wall MI 
2- Infr.  Wall MI 
 
